🇺🇸 FDA
Pipeline program

Autologous hematopoietic stem cell infusion

IIT2025001

Phase 2 mab active

Quick answer

Autologous hematopoietic stem cell infusion for Prolonged Cytopenia Following CAR-T Therapy is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Prolonged Cytopenia Following CAR-T Therapy
Phase
Phase 2
Modality
mab
Status
active

Clinical trials